Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game

Immunotherapy ◽  
2015 ◽  
Vol 7 (5) ◽  
pp. 477-479 ◽  
Author(s):  
Eytan Ben-Ami ◽  
Jacob Schachter
Keyword(s):  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

A randomized, prospective evaluation comparing intensity of lymphodepletion prior to adoptive transfer of tumor infiltrating lymphocytes for patients with metastatic melanoma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3006-3006 ◽  
Author(s):  
Stephanie L. Goff ◽  
Mark Dudley ◽  
Deborah E. Citrin ◽  
Robert Somerville ◽  
John R Wunderlich ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Prospective Evaluation ◽  
Infiltrating Lymphocytes

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2007 ◽  
Vol 56 (11) ◽  
pp. 1853-1860 ◽  
Author(s):  
Amir Khammari ◽  
Jean-Michel Nguyen ◽  
Marie Christine Pandolfino ◽  
Gaëlle Quereux ◽  
Anabelle Brocard ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Long Term Follow Up ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

scholarly journals Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma

2016 ◽  
Vol 34 (20) ◽  
pp. 2389-2397 ◽  
Author(s):  
Stephanie L. Goff ◽  
Mark E. Dudley ◽  
Deborah E. Citrin ◽  
Robert P. Somerville ◽  
John R. Wunderlich ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Adoptive Transfer ◽  
Tumor Regression ◽  
Laboratory Data ◽  
Tumor Infiltrating Lymphocytes ◽  
Complete Response ◽  
Adoptive Cell Transfer ◽  
Cell Transfer ◽  
Sequential Trials ◽  
Infiltrating Lymphocytes

Purpose Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%). Addition and intensification of total body irradiation (TBI) to the preparative lymphodepleting chemotherapy regimen in sequential trials improved objective partial and complete response (CR) rates. Here, we evaluated the importance of adding TBI to the adoptive transfer of tumor-infiltrating lymphocytes (TIL) in a randomized fashion. Patients and Methods A total of 101 patients with metastatic melanoma, including 76 patients with M1c disease, were randomly assigned to receive nonmyeloablative chemotherapy with or without 1,200 cGy TBI before transfer of tumor-infiltrating lymphcytes. Primary end points were CR rate (as defined by Response Evaluation Criteria in Solid Tumors v1.0) and overall survival (OS). Clinical and laboratory data were analyzed for correlates of response. Results CR rates were 24% in both groups (12 of 50 v 12 of 51), and OS was also similar (median OS, 38.2 v 36.6 months; hazard ratio, 1.11; 95% CI, 0.65 to 1.91; P = .71). Thrombotic microangiopathy was an adverse event unique to the TBI arm and occurred in 13 of 48 treated patients. With a median potential follow-up of 40.9 months, only one of 24 patients who achieved a CR recurred. Conclusion Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival > 3 years. Results were similar using chemotherapy preparative regimens with or without addition of TBI.

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

2002 ◽  
Vol 51 (10) ◽  
pp. 539-546 ◽  
Author(s):  
Brigitte Dréno ◽  
Jean-Michel Nguyen ◽  
Amir Khammari ◽  
Marie Pandolfino ◽  
Marie Tessier ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Stage Iii ◽  
Melanoma Tumor ◽  
Stage Iii Melanoma ◽  
Infiltrating Lymphocytes

Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 8510-8510 ◽  
Author(s):  
R. Shapira-Frommer ◽  
M. Besser ◽  
I. Kuchuk ◽  
R. Nave ◽  
D. Zippel ◽  
...  
Keyword(s):  
Metastatic Melanoma ◽  
Adoptive Transfer ◽  
Tumor Infiltrating Lymphocytes ◽  
Short Term ◽  
Melanoma Patients ◽  
Infiltrating Lymphocytes

scholarly journals Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

1990 ◽  
Vol 171 (1) ◽  
pp. 249-263 ◽  
Author(s):  
R B Cameron ◽  
P J Spiess ◽  
S A Rosenberg
Keyword(s):  
Antitumor Activity ◽  
Adoptive Transfer ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Prolonged Survival ◽  
Whole Body ◽  
Local Tumor ◽  
Tumor Irradiation ◽  
B Mice ◽  
Infiltrating Lymphocytes

The adoptive transfer of tumor-infiltrating lymphocytes (TIL) with the concomitant administration of IL-2 has been shown to mediate the regression of established 6- and 14-d murine hepatic and pulmonary metastases. For successful immunotherapy with TIL, however, pretreatment with either cyclophosphamide (CP) or whole body irradiation (WBX) was required. The exact mechanism of CP and WBX augmentation of TIL antitumor activity remains unknown, but the elimination of Ts cells has been frequently invoked as an explanation. To address this possibility and to determine if local tumor irradiation (LTX) could synergize with TIL as well as WBX, we investigated the effect of LTX on the therapeutic efficacy of TIL and IL-2 in the treatment of multiple 7-d murine hepatic metastases. Experiments studying the treatment of a weakly immunogenic murine adenocarcinoma, MC-38, showed prolonged survival of mice treated with the combination of IL-2, TIL, and either LTX or WBX, compared with treatment with radiation alone or radiation plus IL-2 controls (p less than 0.0001). In addition, therapy with LTX and IL-2 prolonged survival, compared with LTX administration alone, whereas therapy with WBX combined with IL-2 did not alter survival. This augmentation of TIL-mediated antitumor activity was dependent on the dose of radiation used. To assess the possibility that tumor-associated Ts cells inhibit the function of adoptively transferred TIL in animals with 7-d metastatic tumor and are eliminated by WBX and LTX, we repeated the above experiments leaving some tumor unirradiated. Mice underwent either LTX or limited LTX, which included only the right side of the liver (LTX1/2). The number of right- and left-sided metastases were then individually counted. These studies showed that the reduction in the number of right-sided metastases was identical between the two groups and that the presence of left-sided tumor in the LTX1/2 group did not suppress the observed antitumor activity of TIL against irradiated tumor. Additional evidence against the elimination of suppressor cells as an important mechanism in radiation-induced augmentation of TIL antitumor activity was provided by experiments studying the effectiveness of TIL in thymectomized, lethally irradiated, and reconstituted B mice. Unless CP was administered before the adoptive transfer of TIL, therapy with IL-2 and TIL in these B mice was ineffective in the absence of demonstrable T lymphocytes.(ABSTRACT TRUNCATED AT 400 WORDS)

Sign in / Sign up

Export Citation Format

Share Document